Midkine: A Novel Biomarker to Predict Malignancy in Patients with Nodular Thyroid Disease

Table 1

Demographic and clinical characteristics in relation to serum midkine (SMK) and nodular midkine (NMK) concentrations.

Demographic and clinical characteristics	SMK	NMK
Gender
Female	0.60	0.52
Male	0.63 (0.30–4.97)	0.68 (0.35–1.73)
	0.912	0.223
Age (years)
<40	0.67 (0.37–4.97)	0.56 (0.38–1.73)
40–59	0.60 (0.30–2.77)	0.52 (0.35–1.45)
≥60	0.60 (0.40–2.03)	0.55 (0.37–0.82)
	0.396	0.298
TSH (µIU/mL)
<0.4	0.57 (0.33–2.03)	0.52 (0.35–0.82)
0.4–4	0.63 (0.30–4.97)	0.53 (0.35–1.73)
>4	0.63 (0.50–1.37)	0.58 (0.43–0.62)
	0.467	0.529

BMI: body mass index; TSH: thyroid stimulating hormone.